Second Regular Session Seventy-third General Assembly STATE OF COLORADO

INTRODUCED

LLS NO. 22-0377.03 Alana Rosen x2606

HOUSE BILL 22-1116

HOUSE SPONSORSHIP

Valdez A., Hooton

SENATE SPONSORSHIP

Ginal,

House Committees

Senate Committees

Public & Behavioral Health & Human Services

A BILL FOR AN ACT

101 CONCERNING ESTABLISHING A POLICY REVIEW PANEL TO STUDY
102 PLANT-BASED MEDICINES TO SUPPORT MENTAL HEALTH.

Bill Summary

(Note: This summary applies to this bill as introduced and does not reflect any amendments that may be subsequently adopted. If this bill passes third reading in the house of introduction, a bill summary that applies to the reengrossed version of this bill will be available at http://leg.colorado.gov.)

The bill creates the plant-based medicine policy review panel (policy review panel). The purpose of the policy review panel is to study the use of plant-based medicines to support mental health. The policy review panel operates for one year. The policy review panel shall submit a report on its findings and policy recommendations to the house of representatives public and behavioral health and human services

committee and the senate health and human services committee, or any successor committees; the governor; and the department of human services.

The bill defines "plant-based medicine" as a naturally occurring hallucinogenic plant-based compound. Forms of plant-based medicine only include psilocybin, psilocyn, dimethyltryptamine, and ibogaine.

1 Be it enacted by the General Assembly of the State of Colorado: 2 **SECTION 1.** In Colorado Revised Statutes, add 26-1-143 as 3 follows: 4 26-1-143. Plant-based medicine policy review panel - created 5 - duties - report - definitions - repeal. (1) AS USED IN THIS SECTION, 6 UNLESS THE CONTEXT OTHERWISE REQUIRES: 7 (a) "FIRST NATIONS PEOPLE" MEANS ANY INDIGENOUS OR 8 ABORIGINAL GROUP THAT IS OFFICIALLY RECOGNIZED BY THE FEDERAL 9 GOVERNMENT. 10 (b) "PLANT-BASED MEDICINE" MEANS A NATURALLY OCCURRING 11 HALLUCINOGENIC PLANT-BASED COMPOUND. FOR THE PURPOSES OF THIS 12 DEFINITION, "PLANT-BASED MEDICINE" INCLUDES ONLY PSILOCYBIN, 13 PSILOCYN, DIMETHYLTRYPTAMINE (SOME TRADE OR OTHER NAMES: 14 DMT.), AND IBOGAINE (SOME TRADE AND OTHER NAMES: 7 - E T H Y L - 6, 6 B, 7, 8, 9, 10, 12, 13 - O C T A H Y D R O - 2 -15 16 METHOXY-6,9-METHANO-5H-PYRIDO [1', 2':1,2] AZEPINE [5,4-B] INDOLE; 17 TABERNANTHE IBOGA.). 18 (c) "PLANT-BASED MEDICINE POLICY REVIEW PANEL" OR "POLICY 19 REVIEW PANEL" MEANS THE PLANT-BASED MEDICINE POLICY REVIEW 20 PANEL CREATED IN SUBSECTION (2) OF THIS SECTION. 21 (2) THERE IS CREATED THE PLANT-BASED MEDICINE POLICY

REVIEW PANEL IN THE STATE DEPARTMENT. THE PURPOSE OF THE POLICY

22

-2- HB22-1116

1	REVIEW PANEL IS TO STUDY THE USE OF PLANT-BASED MEDICINES TO
2	SUPPORT MENTAL HEALTH, REPORT ITS FINDINGS, AND MAKE POLICY
3	RECOMMENDATIONS TO THE GENERAL ASSEMBLY, THE GOVERNOR, AND
4	THE STATE DEPARTMENT.
5	(3) (a) The policy review panel consists of seventeen
6	MEMBERS APPOINTED PURSUANT TO SUBSECTION (3)(b) OF THIS SECTION.
7	(b) THE MEMBERSHIP OF THE POLICY REVIEW PANEL AND
8	APPOINTING AUTHORITIES ARE AS FOLLOWS:
9	(I) THE GOVERNOR SHALL APPOINT THE FOLLOWING ELEVEN
10	MEMBERS:
11	(A) ONE MEMBER REPRESENTING A STATEWIDE ORGANIZATION OF
12	PHYSICIANS;
13	(B) ONE MEMBER REPRESENTING A STATEWIDE ORGANIZATION OF
14	PHARMACISTS;
15	(C) ONE MEMBER REPRESENTING A STATEWIDE ORGANIZATION OF
16	ALTERNATIVE MEDICINE PHYSICIANS;
17	(D) Two members representing alternative plant-based
18	MEDICINE ADVOCATES;
19	(E) ONE MEMBER REPRESENTING PHYSICIANS WHO USE OR HAVE
20	USED PLANT-BASED MEDICINES IN THE PHYSICIANS' MEDICAL PRACTICES;
21	(F) ONE MEMBER REPRESENTING A STATEWIDE ORGANIZATION
22	SERVING VETERANS;
23	(G) ONE MEMBER REPRESENTING EXPERTS WHO USE PLANT-BASED
24	MEDICINES FOR RELIGIOUS PURPOSES;
25	(H) ONE MEMBER REPRESENTING FIRST NATIONS PEOPLE;
26	(I) ONE MEMBER REPRESENTING CERTIFIED ADDICTION
2.7	COUNSELORS: AND

-3- НВ22-1116

1	(J) ONE MEMBER REPRESENTING HARM REDUCTION ADVOCATES;
2	(II) THE PRESIDENT OF THE SENATE, THE MINORITY LEADER OF THE
3	SENATE, THE SPEAKER OF THE HOUSE OF REPRESENTATIVES, AND THE
4	MINORITY LEADER OF THE HOUSE OF REPRESENTATIVES COLLECTIVELY
5	SHALL APPOINT THE FOLLOWING SIX MEMBERS:
6	(A) ONE MEMBER REPRESENTING LAW ENFORCEMENT AGENCIES;
7	(B) ONE MEMBER REPRESENTING SHERIFF'S DEPARTMENTS;
8	(C) ONE MEMBER REPRESENTING CRIMINAL DEFENSE ATTORNEYS;
9	(D) ONE MEMBER REPRESENTING THE OFFICE OF STATE PUBLIC
10	DEFENDER CREATED IN SECTION 21-1-101;
11	(E) ONE MEMBER REPRESENTING AN OFFICE OF THE DISTRICT
12	ATTORNEY; AND
13	(F) ONE MEMBER REPRESENTING ATTORNEYS WITH A PRACTICE
14	FOCUSED ON PLANT-BASED MEDICINES.
15	(c) THE APPOINTING AUTHORITIES SHALL MAKE APPOINTMENTS ON
16	OR BEFORE AUGUST $1,2022$. The term of the appointment is for the
17	DURATION OF THE POLICY REVIEW PANEL. THE APPOINTING AUTHORITIES
18	SHALL FILL ANY VACANCY SUBJECT TO THE SAME QUALIFICATIONS AS THE
19	INITIAL APPOINTMENT. IN MAKING APPOINTMENTS TO THE POLICY REVIEW
20	PANEL, THE APPOINTING AUTHORITIES SHALL ENSURE THAT THE
21	MEMBERSHIP OF THE POLICY REVIEW PANEL REFLECTS THE RACIAL,
22	ETHNIC, CULTURAL, AND GENDER DIVERSITY OF THE STATE, INCLUDING
23	REPRESENTATION OF ALL AREAS OF THE STATE.
24	(d) EACH MEMBER OF THE POLICY REVIEW PANEL SERVES WITHOUT
25	COMPENSATION BUT IS ENTITLED TO RECEIVE REIMBURSEMENT FOR
26	ACTUAL AND NECESSARY EXPENSES THE MEMBER INCURS IN THE
27	PERFORMANCE OF THE MEMBER'S DUTIES AS A MEMBER OF THE POLICY

-4- HB22-1116

1	REVIEW PANEL.
2	(4) THE MEMBERS OF THE POLICY REVIEW PANEL SHALL SELECT A
3	CHAIR AND A VICE-CHAIR FROM AMONG ITS MEMBERS. THE CHAIR AND
4	VICE-CHAIR SHALL SERVE FOR THE DURATION OF THE POLICY REVIEW
5	PANEL.
6	(5) THE POLICY REVIEW PANEL SHALL CONVENE THE FIRST
7	MEETING OF THE POLICY REVIEW PANEL NO LATER THAN OCTOBER $1,2022$
8	THE POLICY REVIEW PANEL SHALL MEET UNTIL OCTOBER 1, 2023, WITH
9	THE NUMBER OF MEETINGS SET AT THE DISCRETION OF THE POLICY REVIEW
10	PANEL. THE CHAIR MAY CALL ADDITIONAL MEETINGS AS NECESSARY FOR
11	THE POLICY REVIEW PANEL TO FULFILL ITS DUTIES. THE POLICY REVIEW
12	PANEL SHALL ESTABLISH PROCEDURES TO ALLOW MEMBERS OF THE POLICY
13	REVIEW PANEL TO PARTICIPATE IN MEETINGS REMOTELY.
14	(6) (a) Pursuant to subsection (2) of this section, the policy
15	REVIEW PANEL SHALL STUDY THE USE OF PLANT-BASED MEDICINES TO
16	SUPPORT MENTAL HEALTH, REPORT ITS FINDINGS, AND MAKE POLICY
17	RECOMMENDATIONS. THE POLICY REVIEW PANEL SHALL, AT A MINIMUM
18	STUDY THE FOLLOWING:
19	(I) ANALYZING AND RECOMMENDING THE RECLASSIFICATION OF
20	THE CONTROLLED SUBSTANCES SCHEDULE, AS DESCRIBED IN PART 2 OF
21	ARTICLE 18 OF TITLE 18, FOR PLANT-BASED MEDICINES;
22	(II) ANALYZING AND RECOMMENDING WHETHER TO
23	DECRIMINALIZE PLANT-BASED MEDICINES;
24	(III) ANALYZING THE WEIGHT AND MEASUREMENTS OF
25	PLANT-BASED MEDICINES;
26	(IV) ANALYZING AND RECOMMENDING A NEW DEFINITION FOR
27	PLANT-BASED MEDICINES;

-5- НВ22-1116

1	(V) PRODUCING, DISTRIBUTING, AND ACCESSING PLANT-BASED
2	MEDICINES SAFELY;
3	(VI) TESTING PLANT-BASED MEDICINES FOR CONTAMINANTS;
4	(VII) DETERMINING THE PROPER DOSAGE OF PLANT-BASED
5	MEDICINES;
6	(VIII) DETERMINING THE PROPER DOSAGE FOR PATIENTS,
7	INCLUDING THOSE WITH MENTAL HEALTH DISORDERS;
8	(IX) DEVELOPING OVERSIGHT AND REGULATION FOR THE USE OF
9	PLANT-BASED MEDICINES IN MEDICAL PRACTICES;
10	(X) Understanding the traditional uses of plant-based
11	MEDICINES;
12	(XI) ANALYZING THE IMPACT OF PLANT-BASED MEDICINES ON
13	EMPLOYMENT POLICIES;
14	(XII) ANALYZING THE IMPACT OF PLANT-BASED MEDICINES ON A
15	PHYSICIAN'S PRACTICE AND LICENSE; AND
16	(XIII) RECOMMENDING ADDITIONAL LEGISLATION TO THE
17	GENERAL ASSEMBLY CONCERNING PLANT-BASED MEDICINES.
18	(b) THE POLICY REVIEW PANEL SHALL CONSULT WITH ADDITIONAL
19	STAKEHOLDERS AS NEEDED TO ADDRESS ALL QUESTIONS NECESSARY TO
20	FINALIZE ITS FINDINGS AND POLICY RECOMMENDATIONS ON THE USE OF
21	PLANT-BASED MEDICINES TO SUPPORT MENTAL HEALTH.
22	(7) On or before January 1, 2024, the policy review panel
23	SHALL SUBMIT A REPORT ON ITS FINDINGS AND RECOMMENDATIONS ON
24	ISSUES IDENTIFIED IN SUBSECTION (6) OF THIS SECTION TO THE HOUSE OF
25	REPRESENTATIVES PUBLIC AND BEHAVIORAL HEALTH AND HUMAN
26	SERVICES COMMITTEE AND THE SENATE HEALTH AND HUMAN SERVICES
27	COMMITTEE, OR ANY SUCCESSOR COMMITTEES; THE GOVERNOR; AND THE

-6- НВ22-1116

	STATE DEPARTMENT.
л	

- 2 (8) This section is repealed, effective July 1, 2025.
- 3 **SECTION 2. Safety clause.** The general assembly hereby finds,
- 4 determines, and declares that this act is necessary for the immediate
- 5 preservation of the public peace, health, or safety.

-7- HB22-1116